Objective: This study was conducted to determine whether b-blocker (BB) therapy is associated with abdominal aortic aneurysm (AAA) sac regression after endovascular abdominal aortic repair (EVAR).
Endovascular abdominal aortic aneurysm (AAA) repair (EVAR) has become a reasonable and common approach in managing AAA. However, aneurysm size regression occurs in only 60% of patients who undergo EVAR. 1 One study showed that aneurysm sac diameter was stable or increased in 36% of EVAR patients without endoleak. 2 Consequently, the potential of pharmacotherapies to enhance aneurysm sac regression and prevent aneurysm sac expansion after EVAR has received attention 3, 4 To date, a promising potential molecular target of pharmacologic treatment for AAA sac regression is matrix metalloproteinases (MMPs), and many studies have suggested that the inhibition of MMP would be a feasible means to suppress the progression of aneurysmal degeneration. 3, 5 Some investigators have shown that b-blockers (BBs) may function as MMP inhibitors. One study showed a selective role for propranolol in inhibiting MMP gene expression. 6 Carvedilol and nebivolol, thirdgeneration BBs, were associated not only with antiinflammatory and antioxidant activity but also with downregulation of MMP levels. 7, 8 Some authors have demonstrated that BB therapy greatly reduces aortic aneurysm growth in patients with small AAA (defined as AAA with a diameter of 3.0-5.0 cm) and in in vivo studies, leading to considerable interest in medical therapy to attenuate aneurysm sac expansion. [9] [10] [11] However, there have been scant data on the effect of BBs on AAA sac regression after EVAR. This study investigated whether BB therapy is beneficial to aneurysm sac regression in patients undergoing EVAR.
METHODS
The study protocol was developed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board. This study does not involve any more than minimal risk to the patient. There are no prescribed interventions associated with the study. A waiver of informed consent was requested and approved by the Institutional Review Board.
Study population and inclusion and exclusion criteria. All consecutive patients admitted to our institution between January 2005 and December 2014 who underwent elective EVAR for infrarenal AAAs were evaluated. Patients were suitable for inclusion if they had undergone initial successful EVAR for infrarenal AAAs with follow-up of at least 1 year. Because the type of stent graft may influence the degree of aneurysm sac regression after EVAR, we only included patients with the Excluder device (W.L. Gore and Assoc, Flagstaff, Ariz), which was the most commonly used stent graft at our institution during the given time period. 12 The study excluded patients treated for thoracic aortic aneurysm, thoracoabdominal aortic aneurysm, juxtarenal AAA with a short proximal neck #15 mm, ruptured aneurysm, infectious aneurysm, anastomotic pseudoaneurysm, isolated iliac aneurysm, aneurysm associated with family history, or multiple other aneurysms. To limit confounding factors, patients were included only if they met the criteria of treatment success, defined as the absence of the following: (1) type I and III endoleaks on initial post-treatment angiography and followup computed tomography (CT) angiography (CTA), (2) type II endoleak on follow-up CTA; (3) rupture or surgical conversion; and (4) stent graft migration or failure. 13 Any patient with an endoleak seen on follow-up imaging was excluded. The study excluded any of the following: off-label use of the stent graft or adjunctive procedures, including chimney/snorkel technique, sandwich techniques, hybrid EVAR with debranching procedures, or any procedure to eliminate periprocedural endoleak, such as use of proximal aortic cuff, Palmaz stent (Cordis Corp, Bridgewater, NJ), EndoAnchors (Medtronic, Minneapolis, Minn), or sac embolization. Finally, patients with unavailable, incomplete, or missing case notes and those who did not have follow-up imaging or clinical follow-up were excluded.
Index procedure and follow-up. EVAR for the treatment of infrarenal AAA was considered when the maximal diameter was at least 50 mm or when an increase in the maximal diameter of at least 5 mm was observed, or both, over a period of 6 months.
14 Clinical and CTA follow-up were scheduled at 1, 6, and 12 months after EVAR, and yearly thereafter to monitor sac regression or expansion and to detect clinical events.
Study end points. The primary end point was the incidence of AAA sac regression at 1 and 2 years of followup. The incidence of significant sac retraction (SSR), stable sac size, and aneurysm sac growth during the same period served as secondary end points.
Definitions, data collection, and evaluation. The primary end point of the study, AAA sac regression, was defined as a sac shrinkage of $5 mm in the AAA maximal diameter from pre-EVAR to any post-EVAR CTA (based on Society for Vascular Surgery Reporting Standards).
14 AAA sac enlargement was defined as a growth of $5 mm in the AAA maximal diameter from pre-EVAR to any post-EVAR CTA. Patients with a change in maximum AAA diameter between À5 mm and 5 mm were defined as "no change or stable size." SSR was defined as an aneurysmal sac diameter of <3.5 cm after EVAR. 15 End points were assessed at the time of each post-EVAR CTA, compared with pre-EVAR (baseline) CT imaging. To better investigate the relationship between the baseline maximum diameter of the AAA and AAA sac regression, we differentiated between medium and large aneurysms by segmenting the population of patients treated into medium (5.0 to 5.9 cm) and large ($6.0 cm) AAAs. A dedicated board-certified radiologist specializing in vascular imaging and intervention evaluated the CTAs for each patient. Maximal diameter measurement was performed in the axial imaging plane on the selected aortic section by positioning two calipers (external to external). 16 For each patient, the change of maximal diameter was calculated on follow-up CTA in the aforementioned method.
The influence of the type of BB therapy on sac regression was investigated, and BB distribution was detailed. 17 Although the BBs differ with regard to many pharmacologic properties, including b 1 /b 2 adrenergic receptor selectivity, intrinsic sympathomimetic activity, and vasodilatory capabilities, the BB class is commonly divided into three generations of agents. 18 First-generation BBs include propranolol. The second-generation agents exhibit higher affinity binding to b 1 receptors than to b 2 receptors, which include metoprolol, bisoprolol, and atenolol. The third-generation BBs, such as carvedilol and nebivolol, are distinguished from the earlier classes of BBs by their vasodilator activity and nitric oxide production.
Statistical analysis. Categoric variables are expressed as percentages and continuous data as mean 6 standard deviation. All aneurysm sac diameters were submitted to a repeated-measures analysis of variance, analyzing the factors of time and time by presence of BB therapy used interaction. Univariate and multivariate logistic regression analyses were performed to identify possible predictors of AAA sac regression at 1 year. The multivariate analysis was performed using the enter method. Known predictors of AAA sac regression in the previous study, including hypertension, smoking, chronic obstructive pulmonary disease, baseline maximal AAA diameter, and neck diameter plus age and gender as background variable were evaluated. 16, 19 Odds ratios (ORs) along with their 95% confidence intervals (CIs) were reported. A P value of <.05 was considered to be statistically significant. The analyses were performed using SPSS 13 software (SPSS Inc, Chicago, Ill).
RESULTS
We identified 422 patients who underwent EVAR with the Excluder device for their infrarenal AAA between January 2005 and December 2014. With review of the exclusion criteria, 198 patients (87.2% male) were included in the analysis (Fig 1) . Of these, 94 did not receive BB therapy (47.5%), and 104 did receive BBs (52.5%). Baseline characteristics of patients in relation to statin group are given in Table I . The mean age was 76 years.
Compared with the non-BB group, the BB group had a higher prevalence of hypertension (97.1% vs 77.7%; P < .001), coronary artery disease (62.5% vs 35.6%; P ¼ .006), and hyperlipidemia (100% vs 26.7%; P < .001). Medical therapy at follow-up included aspirin in 122 patients (61.6%), angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in 94 (47.5%), and calcium channel blocker (CCB) in 60 (30.3%). The BB group was also more likely to be prescribed an aspirin (71.8% vs 51.1%; P ¼ .003) and statin (74.0% vs 47.9%; P < .001) than the non-BB group (Table I) .
Anatomic parameters are presented in Table II . The average baseline AAA maximum diameter was 58.3 6 8.5 mm, and was <6 cm (medium size) in 129 patients (65.2%) and $6 cm (large size) in 69 patients (34.8%). The average AAA proximal neck diameter was 22.7 6 3.1 mm, with a mean length of 26.4 6 11.2 mm and a mean angle of 28.8 6 18.2 . Overall, the differences between diameters, lengths, and angles profiles of AAAs between the two groups were not statistically significant. However, the proximal neck was significantly longer in the non-BB group (28.4 6 11.5 mm) than in the BB group (24.4 6 10.5 mm; P ¼ .027). Summarized key clinical end points are reported in Table III . Evaluating end points at 1 year were available for all study patients, and 2-year follow-up was available in 104 patients (52.5%). No complications related to the intervention or the stent graft were observed.
There was no statistically significant difference in the incidence of aneurysm sac regression in both groups at 1 year (52.1% in the non-BB group vs 45.2% in the BB group, P ¼ .330) and 2 years (58.5% in the non-BB group vs 64.7% in the BB group; P ¼ .515; Fig 2) . The difference of the change of AAA maximum diameter between two groups did not reach statistical significance at 1 year (À6.0 6 7.0 mm in the non-BB group vs À5.5 6 8.1 mm in the BB group; P ¼ .644) and 2 years (À9.0 6 10.5 mm in the non-BB group vs À9.0 6 10.0 mm in the BB group; P ¼ .977). Repeated-measures analysis of variance showed that changes of aneurysm sac diameter over time were not different significantly between two groups (P ¼ .567; Fig 3) . Similarly, the incidence of SSR was comparable between both groups at 1 year (2.1% in the non-BB group vs 3.8% in the BB group; P ¼ .481) and at 2 years (15.1% in the non-BB group vs 17.6% in the BB group; P ¼ .725). The incidence of stable AAA sac diameter was nonsignificant in both groups at 1 year (47.9% in the non-BB group vs 52.9% in the BB group; P ¼ .481) and 2 years (35.8% in the non-BB group vs 31.4% in the BB group; P ¼ .629).
For subgroup analysis, aneurysms were stratified by size ($6 cm or <6 cm). In patients with medium-size AAAs (<6 cm), the groups showed comparable results for the incidence of AAA sac regression at 1 year (31 To investigate an association between the type of BB and the incidence of AAA sac regression, patients in the BB group were classified according to the type of BB that they were taking during the study period. Of 104 patients taking BBs, 34 (32.7%) were treated with first-generation BBs, 55 (52.9%) were treated with second-generation BBs, and 15 (14.4%) were treated with third-generation BBs. The incidence of AAA sac regression at 1 and 2 years was not significant when the non-BB group was compared with the first-generation and second-generation BB groups. The effect of thirdgeneration BBs on AAA sac regression was not significant at 1 year (52.1% in the non-BB group vs 66.7% in the thirdgeneration BB group; P ¼ .294) and 2 years (58.5% in the non-BB group vs 66.7% in the third-generation BB group; P ¼ .699; Fig 4) .
To also investigate independent predictors of AAA sac regression, logistic regression analyses were performed (Table IV) . For univariate logistic regression analysis, aspirin was associated with decreased odds of AAA sac regression at 1 year (OR, 0.479, 95% CI, 0.267-0.860; P ¼ .014), and a larger baseline maximum diameter of AAA was associated with increased odds of AAA sac receptor blocker, CCB, and statin, BB therapy did not significantly affect the odds of AAA sac regression. However, the presence of peripheral artery disease was associated with decreased odds of AAA sac regression at 1 year (OR, 0.465; 95% CI, 0.231-0.935; P ¼ .032).
DISCUSSION
Overall, AAA sac regression at 1 and 2 years was comparable between both groups. BB therapy was not associated with increased odds of AAA sac regression. The effect of third-generation BB on AAA sac regression was not significant. These results might be explained with baseline characteristics in this study and several published articles regarding BBs and aneurysm sac behavior. In baseline data, the incidence of hypertension, coronary artery disease, and hyperlipidemia were higher in the BB group than in the non-BB group. These factors have been associated with accelerated AAA sac enlargement in previous reports, which might attenuate the effect of BBs. 19, 20 A higher use of aspirin in the BB group than in the non-BB group might have affected the outcomes in this study. 21 One study showed that a lack of AAA sac regression was significantly associated with hyperlipidemia and aspirin use. 22 Although the proportion of statin use was higher in the non-BB group than in the BB group, the beneficial effect of statin on AAA sac regression after EVAR is still controversial.
23,24
AAAs with smaller diameter were correlated with better outcomes than large AAAs in many studies. 25 Armon et al 25 proved that smaller aneurysms are more suitable for EVAR because their anatomy tends to be more compatible with stent graft implantation. Because >60% of our patients had an AAA sized <6 cm, the effect of BB therapy on AAA sac regression may have been attenuated by the procedural effect of EVAR, which excludes the AAA from circulation and induces a decrease in size of the AAA sac. The average length of the proximal neck was longer in the non-BB group than in the BB group. There is some evidence linking sufficient length of proximal neck to better outcome with AAA sac regression after EVAR because of the low incidence of endoleaks. 26 However, this finding is unlikely to explain our result, because this study did not include any endoleak seen on follow-up imaging. Finally, one-third of study patients were taking atenolol or propranolol, which have not been shown to improve long-term cardiovascular prognosis after myocardial infarction or to be effective for improving outcomes in patients with heart failure. 27 Indeed, some authors failed to demonstrate a significant AAA sac regression in patients taking propranolol.
28
Because third-generation BB therapy has a more favorable metabolic and efficacy profile compared with firstand second-generation BB therapy, 29 it is reasonable to question whether they may be more effective in respect to aneurysm sac regression. In this analysis, the number of patients taking third-generation BBs was small (n ¼ 15), which could have led to type 2 error. Although third-generation BBs had no effect on aneurysm sac regression (Fig 4) , their use has been increasing and will represent real-world practice and may require further study. The present guidelines do not recommend BB therapy to prevent aneurysm sac expansion. 30 Theoretically, BB therapy may influence aneurysm sac behavior by inhibiting of MMP. The sample size of this study is likely insufficiently powered to clearly address the role of BB therapy for EVAR patients. This is a limitation of this study that should be followed with further study. BBs have been widely used as antihypertensive medications and are still recommended as first-line agents by international guidelines. 31 Although beyond the scope of the present topic, it is worth mentioning that perioperative administration of BBs is rated as a Class I recommendation in the sense of reducing the risk of adverse cardiac morbidities. 32 Several clinical trials have been focused on the effects of BBs for aneurysm expansion.
One study showed that b-blockade may be associated with a decreased AAA growth rate in patients with small AAAs (n ¼ 136). 33 The authors in another study demonstrated a significantly reduced rate of expansion of AAA in patients receiving BB therapy. 34 In contrast, two prospective trials, however, failed to find a significant reduction in AAA expansion in patients with small AAA and receiving BBs because of a high drop-out rate owing to low compliance and adverse events with BB-related bradycardia and hypotension. 28, 35 In addition, retrospective data show that BB therapy did not appear to have any significant effect on AAA sac regression after EVAR, whereas enhanced AAA sac regression occurred after EVAR in patients taking CCBs. 22 However, their study cohorts (n ¼ 119) included 42 patients (37.5%) who had developed an endoleak, which could be a significant confounding factor for evaluation of aneurysm sac behavior. One might wonder whether BB therapy affects the incidence of endoleak, as well as aneurysm sac behavior, because the role of BB therapy on the evolution of endoleak has not been previously investigated. The association between the reduction in MMP activity and endoleak after EVAR has been evaluated. 36 Considering the effect of BB therapy on reducing MMP activity, a possible relationship between the BB therapy and endoleak reduction may be suggested. However, this study's primary aim was to investigate aneurysm sac behavior on BB therapy, and the presence of an endoleak may be a confounding factor in the evaluation of the association between BB therapy and aneurysm sac behavior. This study was limited to patients treated only with the Excluder device. A recent study showed that the generation of stent graft is an important factor in inducing aneurysm sac regression with similar clinically relevant effects among single models. 37 Furthermore, the structure of Excluder device has been stable over the study period. Although the inclusion of different stent grafts may be helpful in the future, this study attempted to limit bias and confounding factors by limiting the sample to a single graft. The use of only one type of stent graft and exclusion of any endoleak limited eligible candidates for our study from 422 in the beginning to 198 for the analysis; however, this study has a relatively large study cohort (n ¼ 198) among studies evaluating the role of BBs on aneurysm sac behavior after EVAR. These efforts might make our data more homogeneous before any statistical technique is applied. Several limitations are inherent to this study. The first limitation is the relatively short follow-up period of only 2 years. Even though the possibility of late benefits from BB therapy may occur if we studied a 5-year or 10-year cohort, this would likely require a larger study population. The relative stability of the changes at 1 and 2 years we felt was important and may make later changes less likely albeit worth further study.
The second limitation is its retrospective nature and potential selection bias. Patients with more favorable AAA anatomy may be selected for EVAR. Therefore, a successful EVAR with complete exclusion of the AAA sac from the circulation may attenuate the differences of the BBs.
Third, the standard definition of maximum diameter decrease of $5 mm for AAA sac regression was used. Recent reports have suggested that changes in AAA sac volume may provide a more sensitive and earlier manner to detect AAA sac regression. 2 Unfortunately, consistent volume measurements are difficult, and maximum diameter of AAA appears to be a more consistent standard for long-term follow-up. Fourth, maximal diameter measurement was performed in the axial imaging plane on the selected aortic section. We understand that centerline measurements may yield a more accurate result; however, there is inherent variability in creating the centerline. Furthermore, each scan was compared with the prior scans to determine any change in diameter.
Fifth, not all anatomic parameters which may have influenced AAA sac regression, 19 such as maximal common iliac artery diameter, proximal neck diameter and proximal neck length, were measured and analyzed.
CONCLUSIONS
This study did not show that BB therapy is statistically associated with AAA sac regression in patients with EVAR for infrarenal AAA. At the present time, there is likely insufficient evidence to recommend that BB therapy should be initiated for the purpose of AAA sac regression.
